Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hertrampf

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
European Journal of Clinical Pharmacology|January 1, 1987
Enoxacin--a potent inhibitor of theophylline metabolismJ Beckmann, W Elsässer, U Gundert-Remy, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|March 1, 1993
Comparison of fluorescence polarisation immunoassay (FPIA) and high performance liquid chromatography (HPLC) methods for the measurement of flecainide in human plasmaU Hoppe, B Krüdewagen, H Stein, et al.
European Heart Journal|December 1, 1994
Myocardial cyclic AMP and norepinephrine content in human heart failureV Regitz-Zagrosek, R Hertrampf, C Steffen, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Elimination of flecainide as a function of urinary flow rate and pHR Hertrampf, U Gundert-Remy, J Beckmann, et al.
British Journal of Clinical Pharmacology|November 1, 1989
Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotypeA S Gross, G Mikus, C Fischer, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
The influence of the sparteine/debrisoquin phenotype on the disposition of flecainideG Mikus, A S Gross, J Beckmann, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
European Journal of Clinical Pharmacology|January 1, 1987
Enoxacin--a potent inhibitor of theophylline metabolismJ Beckmann, W Elsässer, U Gundert-Remy, et al.
International Journal of Clinical Pharmacology, Therapy, and Toxicology|March 1, 1993
Comparison of fluorescence polarisation immunoassay (FPIA) and high performance liquid chromatography (HPLC) methods for the measurement of flecainide in human plasmaU Hoppe, B Krüdewagen, H Stein, et al.
European Heart Journal|December 1, 1994
Myocardial cyclic AMP and norepinephrine content in human heart failureV Regitz-Zagrosek, R Hertrampf, C Steffen, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Elimination of flecainide as a function of urinary flow rate and pHR Hertrampf, U Gundert-Remy, J Beckmann, et al.
British Journal of Clinical Pharmacology|November 1, 1989
Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotypeA S Gross, G Mikus, C Fischer, et al.
Clinical Pharmacology and Therapeutics|May 1, 1989
The influence of the sparteine/debrisoquin phenotype on the disposition of flecainideG Mikus, A S Gross, J Beckmann, et al.
Pageof 1